Extended Data Table 4.
Safety profile and incidence of treatment-related adverse events according to MedDRA SOC and PT (≥10% in either group) by combination regimen: durvalumab-ceralasertib versus durvalumab plus olaparib, danvatirsen or oleclumab
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.